Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RXDX-106 in Advanced Solid Tumors
NCT03454243Phase 1Terminated
- Sponsor
- Roche
- Start
- Feb 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RXDX-106 in solid tumor, sponsored by Roche. Primary endpoints: Dose Limiting Toxicities at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started Feb 2018; status: terminated.
02
Drugs
RXDX-106
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03454243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03454243.